Unclassified

Drug company CEOs

Raymond V. Gilmartin

Kaufman, Marc. "Merck CEO Resigns as Drug Probe Continues." 6 May 2005. Washington Post.
http://www.washingtonpost.com/wp-dyn/content/article/2005/05/05/AR200505...

Merck & Co.'s longtime leader Raymond V. Gilmartin abruptly resigned yesterday on the same day congressional investigators released a slew of documents detailing how the company continued to aggressively promote its arthritis drug Vioxx after it knew of potentially serious safety concerns.

Amgen's 10-K, section on Risk Factors, for fiscal year ended December 31, 2012

From Amgen's 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.

Item 1A. RISK FACTORS

AstraZeneca's 20-F, section on Risk Factors, for fiscal year ended December 31, 2012

From AstraZeneca's 20-F, section on Risk Factors, for fiscal year ended December 31, 2012.

Number of words in Item 1A: 8621
Compulsory licensing of patents: 45

3D. Risk Factors

Eli Lilly's 10-K, section on Risk Factors, for fiscal year ended December 31, 2012

From Eli Lilly's 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.

Number of words in Item 1A: 2168
Compulsory licensing of patents: 0

Item 1A. Risk Factors

Gilead's 10-K, section on Risk Factors, for fiscal year ended December 31, 2012

From Gilead's 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.

Number of words in section 1A: 12709
Words on compulsory licenses: 396

ITEM 1A. RISK FACTORS

Johnson & Johnson's 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.

From Johnson & Johnson's 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.

Number of words in Item 1A: 1314
Compulsory licensing of patents: 0

Item 1A.RISK FACTORS

Roche's Risk Management and Compliance site, section on Risk Factors, dated May 2012.

From Roche's Risk Management and Compliance site, section on Risk Factors, dated May 2012.

Number of words in Risk Factor document: 360
Compulsory licensing of patents: 0

Risk factors

Principal risks and uncertainties

Sanofi's 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.

From Sanofi's 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.

Number of words in Item 3D: 10577
Compulsory licensing of patents: 43

3D. Risk Factors

GlaxoSmithKline's 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.

From GlaxoSmithKline's 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.

Number of words in Item 3D: 6304
Compulsory licensing of patents: 42

3.D Risk factors

Principal risk factors and uncertainties

Novartis' 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012

From Novartis' 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.

Number of words in Item 3D: 10297
Compulsory licensing of patents: 55
Earthquake risk: 96

3.D Risk Factors

Syndicate content